Eli Lilly’s blockbuster diabetes drug Mounjaro has gained a major new use in the United States after the Food and Drug Administration approved it to help reduce the risk of heart attack and stroke in adults with type 2 diabetes who face a high risk of cardiovascular events.
The decision gives Lilly another important foothold in the rapidly expanding market for GLP-1 medicines, where drugmakers are increasingly seeking to prove that the benefits of these treatments extend well beyond blood sugar control and weight loss.
-copy-29e15046.jpeg?w=600)
